TACI, (Transmembrane activator and CAML interactor)

Cat# MBS629740-0,05mg

Size : 0.05mg

Brand : MyBiosource

Contact local distributor :


Phone : +1 850 650 7790

TNFRSF13B Antibody – Goat Polyclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS629740

MBS629740 is an antibody targeting TNFRSF13B. Also known as TACI, (Transmembrane activator and CAML interactor). Reactive in Human. Host: Goat. More details

Product Overview

Online Datasheet in PDF
Product Name
TACI (TNFRSF13B), Polyclonal Antibody
Full Product Name
TACI, (Transmembrane activator and CAML interactor)
Product Gene Name
anti-TNFRSF13B antibody
Product Synonym Names
Anti -TACI, (Transmembrane activator and CAML interactor)
Clonality
Polyclonal
Isotype
IgG
Host
Goat
Species Reactivity
Human
Form/Format
Supplied as a lyophilized powder in 0.5X PBS, pH 7.2.
Purity/Purification
Affinity Purified
Puri ed by af nity chromatography.
Specificity
Recognizes human TACI.
Preparation and Storage
Lyophilized powder may be stored at 4 degree C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20 degree C. Reconstituted product is stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Molecular Weight
31,816 Da
Chromosome Location
Chromosome: 17; NC_000017.10 (16842398..16875432, complement). Location: 17p11.2
OMIM
240500
3D Structure
ModBase 3D Structure for O14836
Immunogen
Highly pure (>98%) recombinant h-TACI.
Reconstitution
When reconstituted in sterile water to a concentration of >0.2mg/ml the antibody is stable for at least six weeks at 2-40C.

Product Categories/Family for anti-TNFRSF13B antibody

Antibodies; Abs to Growth Factors; Cytokines
Applications Tested/Suitable for anti-TNFRSF13B antibody
ELISA (EL/EIA), Western Blot (WB), Neutralization
Application Notes for anti-TNFRSF13B antibody
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of h-TACI (1ng/ml), a concentration of 0.30-0.50ug/ml of this antibody is required.
ELISA: To detect h-TACI by direct ELISA (using 100ul/well antibody solution) a concentration of at least 0.5ug/ml of this antibody is required. This antigen af nity puri ed antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2-0.4ng/well of recombinant h-TACI.
Western Blot: To detect h-TACI by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant h-TACI is 1.5-3ng/lane, under either reducing or non-reducing conditions.

Other Notes

Small volumes of anti-TNFRSF13B antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for TNFRSF13B. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
tumor necrosis factor receptor superfamily member 13B
NCBI Official Synonym Full Names
tumor necrosis factor receptor superfamily, member 13B
NCBI Official Symbol
TNFRSF13B
NCBI Official Synonym Symbols
CVID; RYZN; TACI; CD267; CVID2; TNFRSF14B
UniProt Protein Name
Tumor necrosis factor receptor superfamily member 13B
UniProt Synonym Protein Names
Transmembrane activator and CAML interactor
Protein Family
Tumor necrosis factor receptor superfamily
UniProt Gene Name
TNFRSF13B
UniProt Synonym Gene Names
TACI
UniProt Entry Name
TR13B_HUMAN
NCBI Protein Information
tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor

NCBI Summary for TNFRSF13B

The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
Show more

UniProt Comments for TNFRSF13B

TNFRSF13B: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T- cell function and the regulation of humoral immunity. Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2). CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2). Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; Receptor, misc.; Cell cycle regulation

Chromosomal Location of Human Ortholog: 17p11.2

Cellular Component: integral to plasma membrane; external side of plasma membrane

Molecular Function: protein binding; receptor activity

Biological Process: cell surface receptor linked signal transduction; B cell homeostasis; hemopoietic progenitor cell differentiation; negative regulation of B cell proliferation

Disease: Immunodeficiency, Common Variable, 2; Immunoglobulin A Deficiency 2
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Products associated with anti-TNFRSF13B antibody

 Reference Product  PubMed Publications
 TNFSF13B antibody  >70 publications with TNFRSF13B and TNFSF13B
 TNFRSF13C antibody  >50 publications with TNFRSF13B and TNFRSF13C
 SDC2 antibody  >2 publications with TNFRSF13B and SDC2
 CAMLG antibody  >2 publications with TNFRSF13B and CAMLG
 CD79A antibody  >1 publications with TNFRSF13B and CD79A
 SDC4 antibody  >1 publications with TNFRSF13B and SDC4

Pathways associated with anti-TNFRSF13B antibody

 Products by Pathway  Pathway Diagram
 Cytokine-cytokine Receptor Interaction Pathway antibodies  Cytokine-cytokine Receptor Interaction Pathway Diagram
 Cytokine-cytokine Receptor Interaction Pathway antibodies  Cytokine-cytokine Receptor Interaction Pathway Diagram
 Intestinal Immune Network For IgA Production Pathway antibodies  Intestinal Immune Network For IgA Production Pathway Diagram
 Intestinal Immune Network For IgA Production Pathway antibodies  Intestinal Immune Network For IgA Production Pathway Diagram
 Primary Immunodeficiency Pathway antibodies  Primary Immunodeficiency Pathway Diagram
 Primary Immunodeficiency Pathway antibodies  Primary Immunodeficiency Pathway Diagram
 Syndecan-2-mediated Signaling Events Pathway antibodies  Syndecan-2-mediated Signaling Events Pathway Diagram
 Syndecan-4-mediated Signaling Events Pathway antibodies  Syndecan-4-mediated Signaling Events Pathway Diagram

Diseases associated with anti-TNFRSF13B antibody

 Disease Name  Pubmed Publications
 Immune System Diseases Antibodies  >105 publications with TNFRSF13B and Immune System Diseases
 Common Variable Immunodeficiency Antibodies  >57 publications with TNFRSF13B and Common Variable Immunodeficiency
 Neoplasms Antibodies  >33 publications with TNFRSF13B and Neoplasms
 Inflammation Antibodies  >14 publications with TNFRSF13B and Inflammation
 Multiple Myeloma Antibodies  >12 publications with TNFRSF13B and Multiple Myeloma
 Immunoglobulin a deficiency 2 Antibodies  >5 publications with TNFRSF13B and Immunoglobulin a deficiency 2
 Hyperplasia Antibodies  >4 publications with TNFRSF13B and Hyperplasia
 Kidney Diseases Antibodies  >4 publications with TNFRSF13B and Kidney Diseases
 Eye Diseases Antibodies  >3 publications with TNFRSF13B and Eye Diseases
 Aneuploidy Antibodies  >2 publications with TNFRSF13B and Aneuploidy

Organs/Tissues associated with anti-TNFRSF13B antibody

 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >137 publications with TNFRSF13B and Blood
 Spleen Antibodies  >19 publications with TNFRSF13B and Spleen
 Lymph Antibodies  >4 publications with TNFRSF13B and Lymph
 Mixed Antibodies  >1 publications with TNFRSF13B and Mixed
 Intestine Antibodies  >1 publications with TNFRSF13B and Intestine